Q: On 26 June 2018 we were told that "ClearView reviewed over...

Q: On 26 June 2018 we were told that "ClearView reviewed over 300 potential indications and then assessed the selected candidates based on a robust and comprehensive analysis of scientific rationale, clinical development feasibility and commercial opportunity". As a result, Cynata selected CLI to proceed as our next clinical target. We have then planned the trial and received approval. In April 2020, due to COVID-19, commencement of patient recruitment was put on hold.
Have there been any material changes affecting ClearView's assumptions that would explain why our previous prime target is has fallen of the list?
We are still well funded and should have enough staff to run 3 trials (GvHD, DFU & CLI) ourselves (see Cap Raise presentation 11/12/20 - IPF, Renal & DFU, with Renal now being run by LUMC with us providing the cells only).

Q: Out of the 3 indications mentioned in that presentation (11/12/20), apart from an update on the high potency of Cymerus MSCs in a preclinical model of IPF back in June 2022, there hasn't really been much of a progress update. Given that in December 2020 "Preparation for clinical development programs underway" listed as next steps, it begs the question: where are we at?
Are we still pursuing this indication?

Q: When will FCDI be ready to supply us with Cymerus MSCs for our further pre-clinical and clinical development?
Initially, Waisman was meant to supply the cells for FujiFilm's P2 trial in GvHD in the US.
Given the changes and delay, is FCDI now ready to supply us with the cells for our P2 GvHD trial in the US?

Q: What happened to the "Joint Cynata-University of Melbourne Study Receives Funding Under Victorian Medical Research Accelerator Fund [...] for a study investigating advanced materials for the manufacturing and delivery of highly potent mesenchymal stem cells (MSCs)" dated 11/03/19?
Has the study moved forward as planned?